Avanafil - VIVUS

Drug Profile

Avanafil - VIVUS

Alternative Names: Spedra; Stendra; TA-1790; Zepeed

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Endo International; JW Pharmaceutical; Menarini; VIVUS
  • Class Erectile dysfunction therapies; Pyrimidines; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Erectile dysfunction

Highest Development Phases

  • Marketed Erectile dysfunction
  • Discontinued Female sexual dysfunction; Premature ejaculation

Most Recent Events

  • 27 Mar 2017 Avanafil is available for licensing in Africa, Middle East, Turkey, Commonwealth of Independent States as of 27 Mar 2017.
  • 27 Mar 2017 Avanafil is no longer licensed to Sanofi in Africa, Middle East, Turkey and the Commonwealth of Independent States including Russia
  • 05 Oct 2016 Avanafil licensed to Metuchen Pharmaceuticals for commercialisation in USA, Canada, South America and India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top